J&J PBS candidate approved

Posted 22 April 2025 AM

The TGA has given its nod to Johnson & Johnson's new lung cancer treatment Lazcluze. The drug, which is used in combination with the company's already approved Rybrevant, has been indicated for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations.

The PBAC was asked to consider the combination for use in first line treatment of patients with epidermal growth factor receptor mutated locally advanced or metastatic (Stage IIIB-IV) NSCLC in March with the outcome due to be announced later this week. With the second half of the combination now approved, J&J will be hopeful of a positive outcome from its new listing request.

To see the whole article, please login